Iovance Biotherapeutics Inc’s recent filing unveils that its Chief Commercial Officer Kirby Daniel Gordon acquired Company’s shares for reported $55200.0 on Jun 05 ’25. In the deal valued at $1.84 per share,30,000 shares were bought. As a result of this transaction, Kirby Daniel Gordon now holds 30,000 shares worth roughly $67200.0.
Then, Puri Raj K. bought 5,600 shares, generating $9,743 in total proceeds. Upon buying the shares at $1.74, the Chief Regulatory Officer now owns 206,852 shares.
Before that, Vogt Frederick G bought 25,000 shares. Iovance Biotherapeutics Inc shares valued at $42,250 were divested by the Interim CEO & General Counsel at a price of $1.69 per share. As a result of the transaction, Vogt Frederick G now holds 374,646 shares, worth roughly $0.84 million.
UBS downgraded its Iovance Biotherapeutics Inc [IOVA] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Truist’s analysts, who decreased its forecast for the stock in mid May from “a Buy” to “a Hold”. Citizens JMP also remained covering IOVA and has decreased its forecast on May 09, 2025 with a “Mkt perform” recommendation from previously “Mkt outperform” rating. UBS started covering the stock on October 24, 2024. It rated IOVA as “a Buy”.
Price Performance Review of IOVA
On Friday, Iovance Biotherapeutics Inc [NASDAQ:IOVA] saw its stock fall -3.03% to $2.24. Over the last five days, the stock has gained 9.27%. Iovance Biotherapeutics Inc shares have fallen nearly -69.73% since the year began. Nevertheless, the stocks have fallen -74.01% over the past one year. While a 52-week high of $12.51 was reached on 01/02/25, a 52-week low of $1.64 was recorded on 05/19/25.
Levels Of Support And Resistance For IOVA Stock
The 24-hour chart illustrates a support level at 2.19, which if violated will result in even more drops to 2.14. On the upside, there is a resistance level at 2.30. A further resistance level may holdings at 2.36.
How much short interest is there in Iovance Biotherapeutics Inc?
A steep rise in short interest was recorded in Iovance Biotherapeutics Inc stocks on 2025-05-30, growing by 11.79 million shares to a total of 86.36 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 74.57 million shares. There was a rise of 13.66%, which implies that there is a positive sentiment for the stock.
